These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23935128)

  • 1. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease.
    Döcke S; Lock JF; Birkenfeld AL; Hoppe S; Lieske S; Rieger A; Raschzok N; Sauer IM; Florian S; Osterhoff MA; Heller R; Herrmann K; Lindenmüller S; Horn P; Bauer M; Weickert MO; Neuhaus P; Stockmann M; Möhlig M; Pfeiffer AF; von Loeffelholz C
    Eur J Endocrinol; 2013 Nov; 169(5):547-57. PubMed ID: 23935128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease.
    Kajor M; Kukla M; Waluga M; Liszka Ł; Dyaczyński M; Kowalski G; Żądło D; Berdowska A; Chapuła M; Kostrząb-Zdebel A; Bułdak RJ; Sawczyn T; Hartleb M
    Pol J Pathol; 2017; 68(2):117-127. PubMed ID: 29025245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
    Pohl R; Haberl EM; Rein-Fischboeck L; Zimny S; Neumann M; Aslanidis C; Schacherer D; Krautbauer S; Eisinger K; Weiss TS; Buechler C
    Eur J Clin Invest; 2017 Jan; 47(1):7-18. PubMed ID: 27797398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver.
    Krautbauer S; Wanninger J; Eisinger K; Hader Y; Beck M; Kopp A; Schmid A; Weiss TS; Dorn C; Buechler C
    Exp Mol Pathol; 2013 Oct; 95(2):199-205. PubMed ID: 23906870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine-Like Receptor 1 mRNA Weakly Correlates with Non-Alcoholic Steatohepatitis Score in Male but Not Female Individuals.
    Neumann M; Meier EM; Rein-Fischboeck L; Krautbauer S; Eisinger K; Aslanidis C; Pohl R; Weiss TS; Buechler C
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice.
    Gruben N; Aparicio Vergara M; Kloosterhuis NJ; van der Molen H; Stoelwinder S; Youssef S; de Bruin A; Delsing DJ; Kuivenhoven JA; van de Sluis B; Hofker MH; Koonen DP
    PLoS One; 2014; 9(4):e96345. PubMed ID: 24781986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic stellate cells and is positively associated with characteristics of non-alcoholic steatohepatitis in mice and men.
    Zimny S; Pohl R; Rein-Fischboeck L; Haberl EM; Krautbauer S; Weiss TS; Buechler C
    Exp Mol Pathol; 2017 Aug; 103(1):1-8. PubMed ID: 28600126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver.
    Wanninger J; Bauer S; Eisinger K; Weiss TS; Walter R; Hellerbrand C; Schäffler A; Higuchi A; Walsh K; Buechler C
    Mol Cell Endocrinol; 2012 Feb; 349(2):248-54. PubMed ID: 22118966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity.
    Chakaroun R; Raschpichler M; Klöting N; Oberbach A; Flehmig G; Kern M; Schön MR; Shang E; Lohmann T; Dreßler M; Fasshauer M; Stumvoll M; Blüher M
    Metabolism; 2012 May; 61(5):706-14. PubMed ID: 22136911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C.
    Kukla M; Adamek B; Waluga M; Zalewska-Ziob M; Kasperczyk J; Gabriel A; Mazur W; Sobala-Szczygieł B; Bułdak RJ; Zajęcki W; Kępa L; Ziora K; Żwirska-Korczala K; Wiczkowski A; Hartleb M
    Biomed Res Int; 2014; 2014():517820. PubMed ID: 25121101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum chemerin and vaspin in non-alcoholic fatty liver disease.
    Kukla M; Zwirska-Korczala K; Hartleb M; Waluga M; Chwist A; Kajor M; Ciupinska-Kajor M; Berdowska A; Wozniak-Grygiel E; Buldak R
    Scand J Gastroenterol; 2010; 45(2):235-42. PubMed ID: 20095887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The expression of chemerin and the influence of sitagliptin on its expression in non-alcoholic fatty liver disease rats complicated with prediabetes].
    Zhang L; Gao XF; Wang YH
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2407-2413. PubMed ID: 30138985
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.
    Bekaert M; Ouwens DM; Hörbelt T; Van de Velde F; Fahlbusch P; Herzfeld de Wiza D; Van Nieuwenhove Y; Calders P; Praet M; Hoorens A; Geerts A; Verhelst X; Kaufman JM; Lapauw B
    Obesity (Silver Spring); 2016 Dec; 24(12):2544-2552. PubMed ID: 27768254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.
    Lu Z; Lu F; Wu L; He B; Chen Z; Yan M
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):383-390. PubMed ID: 32524150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemerin/CMKLR1 ameliorates nonalcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through the JAK2-STAT3 pathway.
    An X; Liu J; Li Y; Dou Z; Li N; Suo Y; Ma Y; Sun M; Tian Z; Xu L
    Peptides; 2021 Jan; 135():170422. PubMed ID: 33144092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse Relationship of the CMKLR1 Relative Expression and Chemerin Serum Levels in Obesity with Dysmetabolic Phenotype and Insulin Resistance.
    Corona-Meraz FI; Navarro-Hernández RE; Ruíz-Quezada SL; Madrigal-Ruíz PM; Castro-Albarrán J; Chavarría-Ávila E; Guzmán-Ornelas MO; Gómez-Bañuelos E; Petri MH; Ramírez-Cedano JI; Aguilar-Aldrete ME; Ríos-Ibarra C; Vázquez-Del Mercado M
    Mediators Inflamm; 2016; 2016():3085390. PubMed ID: 27239101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
    Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
    Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis.
    Shen C; Zhao CY; Wang W; Wang YD; Sun H; Cao W; Yu WY; Zhang L; Ji R; Li M; Gao J
    BMC Gastroenterol; 2014 Feb; 14():39. PubMed ID: 24559185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemerin causes lipid metabolic imbalance and induces passive lipid accumulation in human hepatoma cell line via the receptor GPR1.
    Zhu L; Huang J; Wang Y; Yang Z; Chen X
    Life Sci; 2021 Aug; 278():119530. PubMed ID: 33887347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte expressed chemerin-156 does not protect from experimental non-alcoholic steatohepatitis.
    Pohl R; Eichelberger L; Feder S; Haberl EM; Rein-Fischboeck L; McMullen N; Sinal CJ; Bruckmann A; Weiss TS; Beck M; Höring M; Krautbauer S; Liebisch G; Wiest R; Wanninger J; Buechler C
    Mol Cell Biochem; 2022 Aug; 477(8):2059-2071. PubMed ID: 35449483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.